Trial · NCT06875193
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
NCT06875193, Phase 4, Recruiting, Dong Wha Pharmaceutical Co. Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes. Trials, record NCT06875193. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06875193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
- NCT number
- NCT06875193
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 196 participants, estimated
- Lead sponsor
- Dong Wha Pharmaceutical Co. Ltd.
- Conditions
- Type2diabetes
- Interventions
- DW6012(Dasidiem tab. 10/100mg)
- First posted
- 2025-03-13
- Last updated
- 2025-03-17
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Variance in HbA1c from baseline to 24 weeks on study drug | 24 weeks | Change in HbA1c |
| Secondary | Variance in HbA1c from baseline to 12 weeks on study drug | 12 weeks | Change in HbA1c |
| Secondary | Variance in FPG from baseline to 12, 24 weeks on study drug | 12, 24 weeks | Change in Fasting Plasma Glucose(FPG) |
| Secondary | Variance in TC(mg/dL), TG(mg/dL), HDL(mg/dL), LDL(mg/dL) from baseline to 12, 24 weeks on study drug | 12, 24 weeks | Change in TC, TG, HDL, LDL |
| Secondary | Variance in FLI(Fatty Liver Index), AST, ALT, r-GTP, ALP, HSI(Hepatic steatosis index), Total bilirubin, Albumin, Protein from baseline to 12 and 24 weeks after study drug administration | 12, 24 weeks | FLI(Fatty Liver Index)= 1/(1+exp(-x))×100 HSI(Hepatic steatosis index) = 8×ALT/AST+BMI(+2, if type 2 diabetes yes, +2 if female) |
| Secondary | Variance in Kidney value from baseline to 12, 24 weeks on study drug | 12, 24 weeks | Kidney value: eGFR(CKD-EPI fomulation) ACR(Albumin to Creatine ratio), Creatinine |
| Secondary | Variance in body weight from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Percentage of patients achieving HbA1c of 7.0% or 6.5% or less at 12 and 24 weeks post study drug administration compared to baseline | 12, 24 weeks | Percentage of patients achieving HbA1c of 7.0% or 6.5% or less |
| Secondary | Variance in Insulin from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Percentage of subjects prescribed an rescue drug during this study | during 24weeks(study duration/per subject) | rescue drug |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06875193
GET https://conductscience.org/api/trials/v1/NCT06875193/registered